Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
Azizi
Michel
M
Clinical Investigation Center 9201, Assistance Publique des Hôpitaux de Paris/INSERM, Hôpital Européen Georges Pompidou, Paris, France. michel.azizi@egp.ap-hop-paris.fr
Ménard
Joël
J
D000368:Aged; D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000517:prevention & control; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007674:Kidney Diseases / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications; D011507:Proteinuria / Q000188:drug therapy; D051381:Rats; D012084:Renin-Angiotensin System / Q000187:drug effects*; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000209:etiology
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D000804:Angiotensin II